Why would Co­hen reach out to No­var­tis, but not Roche?; WuXi Bi­o­log­ics blue­prints big R&D/man­u­fac­tur­ing com­plex

→ So why would Trump at­tor­ney Michael Co­hen reach out to sell his ser­vices to No­var­tis, but ig­nore the big Basel ri­val Roche? “I have asked in­ter­nal­ly if we had any con­tact, and that is not the case,” Sev­erin Schwan told Reuters.

→ A boom­ing WuXi Bi­o­log­ics is build­ing a new com­plex in Shi­ji­azhuang, Chi­na that will ex­pand its op­er­a­tions in re­search, de­vel­op­ment and man­u­fac­tur­ing. Its new man­u­fac­tur­ing ops will be built to glob­al cGMP stan­dards. “We are very pleased to es­tab­lish the largest bi­o­log­ics cen­ter in north­ern Chi­na, which will en­able lo­cal com­pa­nies to more ef­fec­tive­ly de­vel­op and man­u­fac­ture bi­o­log­ics and in the mean­time pro­vide a ro­bust sup­ply chain net­work for our glob­al clients. This ex­pan­sion will al­low us great ac­cess to lo­cal tal­ents, mar­kets and gov­ern­ment sup­port,” said Chris Chen, the CEO of WuXi Bi­o­log­ics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER